BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bento CM, Gomes MS, Silva T. Looking beyond Typical Treatments for Atypical Mycobacteria. Antibiotics (Basel) 2020;9:E18. [PMID: 31947883 DOI: 10.3390/antibiotics9010018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Thangavelu K, Krishnakumariamma K, Pallam G, Dharm Prakash D, Chandrashekar L, Kalaiarasan E, Das S, Muthuraj M, Joseph NM. Prevalence and speciation of non-tuberculous mycobacteria among pulmonary and extrapulmonary tuberculosis suspects in South India. J Infect Public Health 2021;14:320-3. [PMID: 33618276 DOI: 10.1016/j.jiph.2020.12.027] [Reference Citation Analysis]
2 Boey M, Liu Z, Teo J, Octavia S, Ahidjo BA, Chew KL. MIC Ranges of Quality Control Strain Mycobacterium peregrinum ATCC 700686 against Rifabutin, Eravacycline, Delafloxacin, Clofazimine, and Bedaquiline. J Clin Microbiol 2020;59:e02306-20. [PMID: 33055183 DOI: 10.1128/JCM.02306-20] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Cantelli CR, Dassonville-Klimpt A, Sonnet P. A review of current and promising nontuberculous mycobacteria antibiotics. Future Med Chem 2021;13:1367-95. [PMID: 34165325 DOI: 10.4155/fmc-2021-0048] [Reference Citation Analysis]
4 Egorova A, Jackson M, Gavrilyuk V, Makarov V. Pipeline of anti-Mycobacterium abscessus small molecules: Repurposable drugs and promising novel chemical entities. Med Res Rev 2021;41:2350-87. [PMID: 33645845 DOI: 10.1002/med.21798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Akrami S, Dokht Khosravi A, Hashemzadeh M. Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study. Pathog Glob Health 2022;:1-11. [PMID: 35261334 DOI: 10.1080/20477724.2022.2049029] [Reference Citation Analysis]
6 Grzegorzewicz A, Paściak M. The key factors contributing to the risk, diagnosis and treatment of non-tuberculous mycobacterial opportunistic infections. Postępy Higieny i Medycyny Doświadczalnej 2021;75:696-710. [DOI: 10.2478/ahem-2021-0050] [Reference Citation Analysis]
7 Moreira AC, Mesquita G, Gomes MS. Ferritin: An Inflammatory Player Keeping Iron at the Core of Pathogen-Host Interactions. Microorganisms 2020;8:E589. [PMID: 32325688 DOI: 10.3390/microorganisms8040589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
8 Kazakova O, Racoviceanu R, Petrova A, Mioc M, Militaru A, Udrescu L, Udrescu M, Voicu A, Cummings J, Robertson G, Ordway DJ, Slayden RA, Șoica C. New Investigations with Lupane Type A-Ring Azepane Triterpenoids for Antimycobacterial Drug Candidate Design. Int J Mol Sci 2021;22:12542. [PMID: 34830423 DOI: 10.3390/ijms222212542] [Reference Citation Analysis]
9 Crilly NP, Ayeh SK, Karakousis PC. The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex. Front Immunol 2020;11:623119. [PMID: 33552087 DOI: 10.3389/fimmu.2020.623119] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Muñoz-Muñoz L, Shoen C, Sweet G, Vitoria A, Bull TJ, Cynamon M, Thompson CJ, Ramón-García S. Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria. Antibiotics (Basel) 2021;10:381. [PMID: 33916775 DOI: 10.3390/antibiotics10040381] [Reference Citation Analysis]
11 Gomes A, Aguiar L, Ferraz R, Teixeira C, Gomes P. The Emerging Role of Ionic Liquid-Based Approaches for Enhanced Skin Permeation of Bioactive Molecules: A Snapshot of the Past Couple of Years. Int J Mol Sci 2021;22:11991. [PMID: 34769430 DOI: 10.3390/ijms222111991] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Strong EJ, Lee S. Targeting Autophagy as a Strategy for Developing New Vaccines and Host-Directed Therapeutics Against Mycobacteria. Front Microbiol 2020;11:614313. [PMID: 33519771 DOI: 10.3389/fmicb.2020.614313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Oh JY, Ko YK, Gim JA. DNA Methylation Profiling for the Diagnosis and Prognosis of Patients with Nontuberculous Mycobacterium Lung Disease. Curr Issues Mol Biol 2021;43:501-12. [PMID: 34203447 DOI: 10.3390/cimb43020038] [Reference Citation Analysis]
14 Senhaji-Kacha A, Esteban J, Garcia-Quintanilla M. Considerations for Phage Therapy Against Mycobacterium abscessus. Front Microbiol 2020;11:609017. [PMID: 33537013 DOI: 10.3389/fmicb.2020.609017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Bento CM, Gomes MS, Silva T. Evolution of Antibacterial Drug Screening Methods: Current Prospects for Mycobacteria. Microorganisms 2021;9:2562. [PMID: 34946162 DOI: 10.3390/microorganisms9122562] [Reference Citation Analysis]